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       There is no known cure or definitive vaccination. Currently the best treatment is supportive 
care in maintaining hemodynamic stability, intravenous treatment for fluid and electrolyte 
imbalances, respiratory support, blood product replacement for signs of hemorrhage, correcting 
coagulopathy and administering antibiotics for infection (Turner, 2014).  
         Healthcare workers and hospital personnel in direct contact with an infected patient MUST 
follow strict protocol to prevent personal exposure and further spread of infection. Universal 
precautions should be followed diligently,  wearing personal protective equipment (PPE), handling 
blood or body fluids with extreme caution for potential exposure. The virus can survive on dry 
surfaces such as door knobs and counters for up to several hours , in semen for up to 3 months, 
and other body fluids anywhere from 1 week to 30 days(CDC, 2014; Bray et al. 2014). Hospital 
grade disinfectants such as bleach are effective for killing the virus from surfaces(CDC, 2014). 
         Strict isolation with “fever surveillance”(Hampton, 2014) of suspected or lab confirmed 
infected patients must be enforced. Hospitals and all healthcare personnel need education on  
correct application and removal of personal protective equipment (donning and doffing). It is 
important to be familiar with institutional regulations on infectious disease, and the plan of 
emergency action in case of a pandemic. There should be strict screening protocols of patients 
through hospital ERs with possible symptoms or virus exposure. 
 
     
         Ebolavirus, or Ebola Virus Disease (EVD), is of 
the filovirus family causing hemorrhagic fever first 
discovered in the African country of Zaire in 1976 
(Turner, 2014; Hampton, 2014) and has gained 
global concern and attention since the recent 
epidemic outbreak in West Africa.  
       There are five known species of Ebola: Zaire, 
Sudan, Ivory Coast, Bundibugyo and Reston, based 
on the region of origination. The Zaire  species has 
been identified as the strain responsible for the 
current outbreak in West Africa, and has spread to 
Liberia, Sierra Leone, Nigeria and Senegal (Centers 
for Disease Control and Prevention,2014; Gostin, 
Lucey & Phelan, 2014).  
       The African fruit bat is most likely the carrier 
,or vector, for the virus. Human infection results 
from direct contact and handling of the infected 
bushmeat of bats, primates, antelopes,  rats and 
other wild animals . Transmission of the virus 
between humans occurs only through close 
contact with bodily fluids (blood, saliva, sweat, 
urine, vomit, breast milk, feces, and semen) of an 
infected  individual (CDC, 2014; Gostin et al., 
2014).  
      The mortality rate for contracting the virus  
may be up 90%, with the recent virus outbreak 
averaging 55-60%(Hampton, T., 2014; CDC, 2014).  
There is currently no known cure or vaccine.  
                           Prevention and Education! 
                 Public education is paramount in preventing the spread of the virus. Education 
would include proper hand washing techniques and  hygiene, what symptoms to monitor 
for, what to do if suspect exposure or infection, the severity/fatality risk of Ebola virus, 
risk factors for transmission, and preventative measures.  
.  
             Currently there have been 4 lab-confirmed 
Ebolavirus cases in the United States: two imported 
cases, including 1 death, and 2 healthcare acquired 
cases (CDC, 2014).  
          The first U.S. case was a patient who had 
recently traveled from Liberia to Dallas, TX., 
developing symptoms four days after his arrival. 
Lab confirmation was received on October 30th, this 
patient died one week later. The following two 
cases were healthcare workers who provided direct 
care for this patient and tested positive for Ebola 
on October 10th and October 15th, respectively 
(CDC, 2014). Both have  fully recovered and have 
been released from  isolation (CDC, 2014).  The 
most recent case is a healthcare worker in New 
York who had returned from Liberia and tested 
positive on Oct. 23th and remains under isolation 
precautions (CDC, 2014).  
        The 2014 Ebola outbreak is the largest 
outbreak in history. As of Nov 7, the total number 
of  cases was 13,241; total lab-confirmed cases  
8,142; and total death count of 4,950 (CDC, 2014).  
 
         Signs and symptoms of  an Ebolavirus infection may include respiratory 
infection with pharyngitis and nonproductive cough, flu-like symptoms, fever 
greater than 101.5°F, severe headache, muscle pain/ myalgia, body aches, 
weakness/malaise, abdominal pain, nausea, vomiting, diarrhea, diffuse 
erythematous nonpuritic maculopapular rash(Bray et al, 2014), dermatitis, 
kidney and liver dysfunction(CDC, 2014; Turner, 2014). Hemorrhage may 
develop with petechiae, bruising, bleeding from mucous membranes, and 
internal bleeding; eventually progressing to multi-organ system failure and 
septic shock (CDC, 2014). 
         Lab findings include leukopenia as lymphopenia later followed by elevated 
neutrophil count with left shift; thrombocytopenia with platelet counts between 
50,000 and 100,000; elevated AST and ALT, elevated PT/PTT consistent with 
disseminated intravascular coagulation; and proteinuria (Bray et al, 2014).   
         Symptoms may begin to develop 2-21 days from exposure to the virus, 
with average onset of 8-10 days. Between days 7-9 symptoms may include 
headache, fatigue, fever, and muscle soreness. Day 10- sudden high fever and 
vomiting blood. Day 11- Bruising, brain damage, bleeding from nose, mouth, 
eyes and anus. Day 12- Loss of consciousness, seizures, massive internal 
bleeding and death (CDC, 2014). 
            Infected individuals typically improve 6 days after the onset of 
symptoms(Bray et al, 2014). Antigen-antibody complexes formed during 
recovery may cause muscle and body aches. More severe, fatal cases will have 
more severe signs and symptoms initially and may quickly progress to 
multiorgan failure and septic shock, with death occurring between 6-16 days 
(Bray et al., 2014).  
          Signs & Symptoms   
 
                 
 
Pathophysiology of Ebolavirus 
 
         The current Ebola outbreak has been declared an 
international public health emergency( WHO,2014). The CDC 
reports the risk of an Ebola outbreak in the U.S. is low, 
recommending limited  travel  to West African countries. 
However, currently there is no ban on travel (Gostin et. al, 
2014).  
         With no known definitive cure or vaccination to prevent 
the Ebola virus, strict adherence to preventing the spread must 
be continued. Hospitals must maintain strict screening protocols 
of all patients who are at risk for exposure.  
          International efforts to prevent the spread of the virus 
have been implemented in major US and West African airports 
through entry and exit screening of travelers for infectious signs 
and symptoms (CDC, 2014).  
        The CDC states the rapid identification of Ebola infection  is 
key to preventing the spread of the virus. “Contact tracing” is 
currently a method used by CDC teams to track down infected 
persons and is described in the following chart from the CDC 
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            Ebolavirus is a single stranded RNA virus that enters the body 
through mucous membranes, breaks in the skin or intravenously and 
attacks many cells of the body including monocytes, phagocytes, 
macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, 
adrenal cortical cells and epithelial cells. (Yen et al., 2011, CDC 2014).  
           The virus migrates from the initial infection site and infects 
macrophages and dendritic cells where viral replication occurs, causing 
cellular apoptosis and leakage of viral particles into the extracellular fluid. 
The replicated virus travels to regional lymph nodes for continued viral 
replication, and subsequently to dendritic cells and macrophages in the 
liver, spleen, thymus and adrenal glands(Bray, Hirsch & Mitty, 2014).The 
virus continues to spread systemically as inflammatory interferon is 
suppressed, infecting hepatocytes, adrenal cortical cells, fibroblasts etc. 
causing significant tissue necrosis.  
            The release of cytokines, chemokines, and other inflammatory 
mediators such as tumor necrosis factor, interleukins, and nitric oxide 
result in a systemic inflammatory response(Bray et al, 2014). Clinical 
manifestations of Ebola infection result from the body’s response to the 
infection rather than  toxicity caused by the virus(Bray et al, 2014).   
Infected macrophages with additional stimulation by inflammatory 
cytokines releases tissue factor  and initiates the coagulation pathway 
causing impaired coagulopathy. In addition to hepatic injury, coagulation 
dysfunction may ultimately lead to hemorrhage (Bray et al, 2014).  
               The body’s adaptive immune system begins to fail as a result of 
impaired dendritic cellular function and lymphocyte apoptosis (Bray et al., 
2014). This attack on adaptive immunity is how the Ebolavirus can cause 
such severe illness and fatality(Bray et al., 2014). Dendritic cells are a 
major site for viral replication, preventing maturation of the cells and their 
ability to present antigens to lymphocytes. There is also massive apoptosis 
of lymphocytes induced by inflammatory mediators and lack of dendritic 
signals (Bray et al, 2014).  
              Ethical considerations exist concerning using 
experimental drugs. There will be limited supplies, many of 
which are still awaiting approval for clinical trials (Gostin et al., 
2014).  Ethical questions remain as to who would have priority 
for treatment, and how and who would make these decisions. 
There can be serious, even fatal risks with experimental 
therapies and prospective recipients would need to be 
educated and understand these risks.  
                Obama administration is working with  specialists 
on setting healthcare policy to support  potential 
experimental treatment therapies  for clinical trials 
(Hampton, 2014). A major influence on the deployment of 
treatment relies highly on international funding. This 
certainly would be a major issue in providing potential 
treatments for thousands of Ebola infected people. See 
additional information regarding international funding for 
Ebola treatment in Africa: 
http://www.who.int/tdr/news/2014/ebola-treatment-
trials/en/.   
         Recovered Ebola patients develop antibodies that may last up to 10 years. 
Convalescent therapy of whole blood or plasma transfusions from these 
individuals has shown promise for recovery(WHO,2014) of infected individuals.  
      The WHO has approved implementation of experimental therapies to treat 
Ebola individuals (Hampton, 2014) with projected availability by early 2015. There 
are several potential vaccines currently undergoing approval for clinical trials. The 
CAd3-ZEBOV vaccine developed by GlaxoSMithKline uses chimpanzee-derived 
adenovirus vector with an Ebola virus gene inserted(WHO,2014). The rVSV-ZEBOV 
vaccine developed in Canada is an attenuated vesicular stomatitis virus found in 
livestock with Ebola gene replacement(WHO, 2014). Additional potential 
treatments include an SiRNA compund (TKM-Ebola), and AVI-7537m, an antisense 
drug (Mullin, 2014; Jarvis, 2014). A recent media release from Japan announced a 
potential treatment Avigan, a polymerase inhibitor, is currently awaiting approval 
for treatment. The antibody compound Zmapp has already been used for 
treatment with both successful and unsuccessful outcomes.  
